Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Product choice and haemophilia treatment in the Netherlands
Autore:
Mauser-Bunschoten, EP; Roosendaal, G; Van den Berg, HM;
Indirizzi:
Univ Utrecht, Med Ctr, Van Creveldklin, NL-3584 CX Utrecht, Netherlands Univ Utrecht Utrecht Netherlands NL-3584 CX 3584 CX Utrecht, Netherlands
Titolo Testata:
HAEMOPHILIA
fascicolo: 1, volume: 7, anno: 2001,
pagine: 96 - 98
SICI:
1351-8216(200101)7:1<96:PCAHTI>2.0.ZU;2-Y
Fonte:
ISI
Lingua:
ENG
Soggetto:
RECOMBINANT FACTOR-VIII; HEMOPHILIA-A; PARVOVIRUS B19; SAFETY;
Keywords:
haemophilia; product; recombinant; treatment;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
13
Recensione:
Indirizzi per estratti:
Indirizzo: Mauser-Bunschoten, EP Univ Utrecht, Med Ctr, Van Creveldklin, C 01-425,Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands Univ Utrecht C 01-425,Heidelberglaan 100 Utrecht Netherlands NL-3584 CX
Citazione:
E.P. Mauser-Bunschoten et al., "Product choice and haemophilia treatment in the Netherlands", HAEMOPHILIA, 7(1), 2001, pp. 96-98

Abstract

In the Netherlands, there is a free choice of product for the treatment ofhaemophilia. Which product is chosen depends on the following considerations: medical, psychological, availability of clotting products, economics and government guidelines. Since the introduction of recombinant product in 1995, the percentage of Dutch patients treated with it has increased from 8%in 1995 to 20% in 1998. In 1999, an average of 48% of patients visiting the Van Creveldkliniek were treated with recombinant product. Children are more of ten treated with recombinant product than adults; 93% of children between 0 and 5 years, 53% of children between 6 and 20 years and 40% of adults are treated with recombinant product.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 14/08/20 alle ore 07:50:13